Hemato-Oncology

Hemato-oncology integrates hematology and oncology, focusing on blood-related diseases originating from sources like the bone marrow and the lymphatic system. It is a dynamic field with ongoing advanced research and clinical trials to enhance treatments for blood-related cancers and disorders. Specialists in rare blood cancers use various diagnostic methods, such as blood tests and bone marrow biopsies, to confirm conditions, effectively manage symptoms, slow disease progression, and enhance patients' quality of life.

Myeloproliferative neoplasms (MPNs) involve excessive blood cell production in the bone marrow, leading to elevated blood cell counts and severe complications like blood clots and strokes. Diagnosis typically involves blood and genetic tests, bone marrow biopsies as well as medical history reviews. Management of MPNs often requires ongoing monitoring and collaboration with other specialists to tailor treatment plans to individual patient needs.

MPNs, including Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis, are chronic conditions requiring lifelong care to ensure the best outcomes and quality of life.

Polycythemia Vera is characterized by excessive production of red blood cells in the bone marrow, leading to thickened blood and increased risk of clots.

Essential Thrombocythemia, marked by excessive platelet production, poses abnormal clotting, stroke, and bleeding risks.

Primary Myelofibrosis is a rare bone marrow disorder characterized by abnormal fibrous tissue growth. It causes bone marrow scarring, impairing its ability to produce blood cells and leading to symptoms such as anemia and enlarged spleen.